Literature DB >> 7601007

New directions for the treatment of chronic myeloid leukaemia.

J M Goldman1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7601007     DOI: 10.2165/00003495-199549050-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  21 in total

1.  Idarubicin-containing regimen and G-CSF are capable of recruiting CD34+/DR- cells with high proliferative potential which sustain Ph-negative polyclonal hematopoiesis.

Authors:  A M Carella; M Podestá; N Pollicardo; E Pungolino; M R Raffo; R Ferrero; G Bergamaschi; V Rosti; M Cazzola; G Saglio
Journal:  Leukemia       Date:  1994-01       Impact factor: 11.528

2.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

Authors:  J M Goldman; R P Gale; M M Horowitz; J C Biggs; R E Champlin; E Gluckman; R G Hoffmann; S J Jacobsen; A M Marmont; P B McGlave
Journal:  Ann Intern Med       Date:  1988-06       Impact factor: 25.391

Review 3.  Treatment of chronic myeloid leukemia by marrow transplantation.

Authors:  R A Clift; F R Appelbaum; E D Thomas
Journal:  Blood       Date:  1993-10-01       Impact factor: 22.113

4.  Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.

Authors:  R Hehlmann; H Heimpel; J Hasford; H J Kolb; H Pralle; D K Hossfeld; W Queisser; H Löffler; B Heinze; A Georgii
Journal:  Blood       Date:  1993-07-15       Impact factor: 22.113

5.  Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.

Authors:  H Ozer; S L George; C A Schiffer; K Rao; P N Rao; D H Wurster-Hill; D D Arthur; B Powell; A Gottlieb; B A Peterson; K Rai; J R Testa; M LeBeau; R Tantravahi; C D Bloomfield
Journal:  Blood       Date:  1993-11-15       Impact factor: 22.113

6.  Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years.

Authors:  D I Marks; J O Cullis; K N Ward; S Lacey; R Syzdlo; T P Hughes; A P Schwarer; E Lutz; A J Barrett; J M Hows; J R Batchelor; J M Goldman
Journal:  Ann Intern Med       Date:  1993-08-01       Impact factor: 25.391

7.  Prognostic discrimination in "good-risk" chronic granulocytic leukemia.

Authors:  J E Sokal; E B Cox; M Baccarani; S Tura; G A Gomez; J E Robertson; C Y Tso; T J Braun; B D Clarkson; F Cervantes
Journal:  Blood       Date:  1984-04       Impact factor: 22.113

8.  Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups.

Authors:  P B McGlave; P De Fabritiis; A Deisseroth; J Goldman; M Barnett; J Reiffers; B Simonsson; A Carella; D Aeppli
Journal:  Lancet       Date:  1994-06-11       Impact factor: 79.321

9.  Autografting for patients with CML in chronic phase: an update. Hammersmith BMT Team LRF Centre for Adult Leukaemia.

Authors:  C Hoyle; R Gray; J Goldman
Journal:  Br J Haematol       Date:  1994-01       Impact factor: 6.998

Review 10.  Autografting in chronic myeloid leukaemia.

Authors:  S G O'Brien; J M Goldman
Journal:  Blood Rev       Date:  1994-06       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.